Visual Universitätsmedizin Mainz

Prof. Dr. med. Tim Zimmermann

Prof. Dr. med. Zimmermann, MHBA
Funktionen: Oberarzt Gastroenterologie und Hepatologie, Station 5B1
Leberambulanz, Transplantationsambulanz
Leiter Transplantationshepatologie
Qualifikationen: Facharzt für Innere Medizin und Gastroenterologe
Medikamentöse Tumortherapie
Sonographie Innere Medizin DEGUM Stufe I
Transplantationsmediziner (European Board of Transplant Medicine - EBTM)
Ernährungsmediziner (DGEM)
Fachkunde Geriatrie
Master of Health Business Administration (MHBA)
tim.zimmermann@unimedizin-mainz.de

Vita (Pdf , 70,6 KB)

Klinische Tätigkeiten und Schwerpunkte

  • Diagnostik und Therapie gastroenterologischer und hepatologischer Erkrankungen.

  • akute und chronische Lebererkrankungen:
    - Fibrose, kompensierte und dekompensierte Leberzirrhose
    - Therapie viraler, nutritiv-toxischer Lebererkrankungen, Fettleber und NASH
    - Vorsorge und Nachsorge zur Lebertransplantation
  • Gastroenterologische diagnostische und interventionelle Endoskopie, ERCP, internistische Laparoskopie, abdominelle Punktionen
  • Abdomen-Sonographie
  • Gastrointestinale Onkologie
  • Konzeption und Durchführung klinischer Studien im Bereich Gastroenterologie und Hepatologie.

Die wissenschaftlichen klinischen und experimentellen Schwerpunkte der Arbeitsgruppe, Mitarbeiter, Promotionen und Publikationen finden Sie hier.

Klinische Studien

Seit 2004-bis dato: Teilnahme an zahlreichen klinischen Studien Phase II-IV als 
Principal Investigator und Subinvestigator
2004 und 2012: Zertifikat Prüfarzt in klinischen Studien, IZKS Mainz,jährliche Aktualisierung
Seit 2012: Selbständige Konzipierung und Durchführung klinischer Studien

Leitlinientätigkeit

01/2016 – bis dato Wissenschaftlicher Sekretär der S3-Leitlinie Hepatitis C
01/2017 – bis dato Mitglied S2k Leitlinie Lebertransplantation

Mitgliedschaften in Fachgesellschaften

• Deutsche Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS)
• Deutsche Gesellschaft für Ultraschall in der Medizin (DEGUM)
• German Association for the Study of the Liver (GASL)
• European Association for the Study of the Liver (EASL)
• Deutsche Transplantationsgesellschaft (DTG)
• Deutsche Gesellschaft für Ernährungsmedizin (DGEM)
• Deutsche Diabetes Gesellschaft (DDG)
• Gastroenterologische Arbeitsgemeinschaft Rheinland-Pfalz/Saarland (GARPS)

Peer-review Aktivitäten

• Drugs
• Journal of Hepatology
• Transplantation
• American Journal of Transplantation
• Alimentary Pharmacology and Therapeutics
• Digestive and Liver Disease
• Journal of Gastrointestinal and Liver Disease
• Journal of Clinical Virology
• Annals of Surgical Oncology
• International Journal of Cancer
• BMC Cancer
• Cancer Communications
• Amino Acids
• Cellular Physiology and Biochemistry
• Zeitschrift für Gastroenterologie

Preise und Aufzeichnungen

• 2008: Förderpreis der Arbeitsgemeinschaft für Gastroenterologie Rheinland-Pfalz und Saarland (GARPS) für experimentelle Gastroenterologie: „EGF supprimiert Hugl-2, das humane Homolog des Drosophila Lgl Tumorsuppressor-Gens.“
• 2008: Reisestipendium DTG: „PTLD nach Lebertransplantation bei Patienten mit immunologischen Erkrankungen.“
• 2009: Reisestipendium DTG: „Risk factors in patients with rapid recurrent HCV related cirrhosis within one year after liver transplantation.“
• 2011: Young Investigator Bursary – EASL: “Recipient CYP2D6*4 poor metabolizer status associates with early fibrosis development after liver transplantation.”
• 2013: Posterpreis der 22. Jahrestagung der Deutschen Transplantationsgesellschaft (DTG): “The genetic signature of the donor organ influences the fibrosis progression after liver transplantation.”
• 2015: Darstein F, ..., Zimmermann T. Förderpreis der Arbeitsgemeinschaft für Gastroenterologie Rheinland-Pfalz und Saarland (GARPS) 2015 für klinische Gastroenterologie: “New onset of diabetes after transplantation is associated with improved patient survival after liver transplantation due to confounding factor.”
• 2017: Darstein F, …, Zimmermann T. Posterpreis der 26. Jahrestagung der Deutschen Transplantationsgesellschaft (DTG) 2017: “Pretransplant coronary artery disease is the strongest predictor for myocardial infarction and cardiac death after liver transplantation.”
• 2017: Wenz T, …, Zimmermann T. Förderpreis der Arbeitsgemeinschaft für Gastroenterologie Rheinland-Pfalz und Saarland (GARPS) 2017 für Gastroenterologie: “Einfluss der Hepatitis C und der antiviralen Therapie auf Endothel, Metabolismus und subklinische Inflammation.”
• 2018: Vollmar J, …, Zimmermann T. Posterpreis der Saarländisch-Pfälzischen Internistengesellschaft (SPIG): “Progression of transthyretin (TTR) amyloidosis after domino liver transplantation in donor and recipient.”

Publikationsverzeichnis (PubMed-chronologisch):


 

1. Metzger JC, Kurz E, von Spee-Mayer C, Kolck G, Bogumil A, Galle PR Zimmermann T. [Chronic granulomatous disease as a rare differential diagnosis of inflammatory bowel disease]. Z Gastroenterol 2018; 56(12): 1507-1512.
2. Labenz C, Toenges G, Schattenberg JM, Nagel M, Sprinzl MF, Nguyen-Tat M, Zimmermann T, Huber Y, Marquardt JU, Galle PR, Wörns MA. Clinical predictors for poor quality of life in patients with covert hepatic encephalopathy. J Clin Gastroenterol. 2018; doi: 10.1097/MCG.0000000000001149.
3. Pflaum J, Zimmermann T. [Hepatitis C: innovations in the last 10 years]. MMW Fortschr Med. 2018; 160(Suppl 3): 66-70.
4. Knop V, Hofmann WP, Buggisch P, Klinker  H, Mauss S, Günther R, Hinrichsen H, Hüppe D, Pfeiffer-Vornkahl H, Simon KG, Berg T, Manns MP, Friedrich-Rust M, German Hepatitis C-Registry. Estimation of liver fibrosis by noncommercial serum markers in comparison with transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral treatment. J Viral Hepat. 2018; doi: 10.1111/jvh.13021.
5. Darstein F, Häuser F, Straub BK, Wenzel JJ, Conradi R, Mittler J, Lang H, Galle PR, Zimmermann T. Hepatitis E virus genotype 3 is a common finding in liver-transplanted patients undergoing liver biopsy for elevated liver enzymes with a low de Ritis ratio and suspected acute rejection: a real-world cohort. Clin Transplant 2018; 32(11): e13411. doi: 10.1111/ctr.13411.
6. Labenz C, Beul L, Toenges G, Schattenberg JM, Nagel M, Sprinzl MF, Nguyen-Tat M, Zimmermann T, Huber Y, Marquardt JU, Galle PR, Wörns MA. Validation of the simplified Animal Naming Test as primary screening tool for the diagnosis of covert hepatic encephalopathy. Eur J Intern Med. 2018; doi: 10.1016/j.ejim.2018.08.008.
7. Vollmar J, Schmid JC, Hoppe-Lotichius M, Barreiros AP, Azizi M, Emrich T, Geber C, Schad A, Weyer V, Otto G, Heise M, Mittler J, Lang H, Galle PR, Zimmermann T. Progression of transthyretin (TTR) amyloidosis in donors and recipients after domino liver transplantation. Transpl Int 2018; 31(11): 1207-1215.
8. Herzer K, Gerken G, Kroy D, Tacke F, Plewe J, Eurich D, Spengler U, Strassburg CP, Welker MW, Pischke S, Sterneck M, Mehrabi A, Weiss KH, Herber A, Berg T, Zimmermann T, Galle PR, Heinzow H, Schmidt H, Markova A, Serfert Y, Manns MP, Zeuzem S, Wedemeyer H. Impact of direct-acting antiviral therapy on the need of liver transplantation related to hepatitis C in Germany. J Hepatol 2018; 69(4): 982-984.
9. Dultz G, Müller T, Petersen J, Mauss S, Zimmermann T, Muche M, Simon KG, Berg T, Zeuzem S, Hüppe D, Böker K, Wedemeyer H, Welzel TM, Leberstiftungs-GmbH Deutschland. Effectiveness and Safety of Direct-Acting Antiviral Combination Therapies for Treatment of Hepatitis C Virus in Elderly Patients: Results from the German Hepatitis C Registry. Drugs Aging 2018; 35(9): 843-857.
10. Schmidt FP*, Zimmermann T*, Wenz T, Schnorbus B, Ostad MA, Feist C, Grambihler A, Schattenberg JM, Sprinzl MF, Münzel T, Galle PR. Interferon- and ribavirin-free therapy with new direct acting antivirals (DAA) for chronic hepatitis C improves vascular endothelial function. Int J Cardiol 2018: 271: 296-300. *Co-Erstautor
11. Maasoumy B, Buggisch P, Mauss S, Boeker KHW, Müller T, Günther R, Zimmermann T, Manns MP, Sarrazin C, Hüppe D, Wedemeyer H, Vermehren J. Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patients. Liver int 2018; 38(11): 1906-1910.
12. Zimmermann T, Jansen PL, Sarrazin C, Vollmar J, Zeuzem S. S3-Leitlinie “Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus (HCV) -Infektion”. Z Gastroenterol 2018; 56(7): e53-e115.
13. Sarrazin C*, Zimmermann T*, Berg T, Neumann UP, Schirmacher P, Schmidt H, Spengler U, Timm J, Wedemeyer H, Wirth S, Zeuzem S. Prophylaxis, diagnosis and therapy of hepatitis-C-virus (HCV) infection: the German guidelines on the management of HCV infection – AWMF-Register-No.: 021/012. Z Gastroenterol 2018; 56(7): 756-838. *Co-Erstautor
14. Labenz C, Baron JS, Toenges G, Schattenberg JM, Nagel M, Sprinzl MF, Nguyen-Tat M, Zimmermann T, Huber Y, Marquardt JU, Galle PR, Wörns MA. Prospective evaluation of the impact of covert hepatic encephalopathy on quality of life and sleep in cirrhotic patients. Aliment Pharmacol Ther 2018; 48(3): 313-321.
15. Foerster F, Mittler J, Darstein F, Heise M, Marquardt JU, Wörns MA, Weinmann A, Sälter L, Hoppe-Lotichius M, Heinrich S, Kloeckner R, Pitton MB, Schattenberg JM, Sprinzl MF, Düber C, Otto G, Lang H, Galle PR, Zimmermann T. Recipient liver function before transplantation influences post-transplantation survival in patients with HCC. Eur J Intern Med. 2018; 55: 57-65.
16. Vollmar J, Lautem A, Closs E, Schuppan D, Kim YO, Grimm D, Marquardt JU, Fuchs P, Straub BK, Schad A, Gründemann D, Schattenberg JM, Gehrke N, Wörns MA, Baumgart J, Galle PR, Zimmermann T. Loss of organic cation transporter 3 (Oct3) leads to enhanced proliferation and hepatocarcinogenesis. Oncotarget 2017; 8(70): 115667-115680.
17. Christensen S, Buggisch P, Mauss S, Böker KHW, Schott E, Klinker H, Zimmermann T, Weber B, Reimer J, Serfert Y, Wedemeyer H. Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice? Addiction 2018; 113(5): 868-882.
18. Darstein F, Hoppe-Lotichius M, Vollmar J, Weyer-Elberich V, Zimmermann A, Mittler J, Otto G, Lang H, Galle PR, Zimmermann T. Pretransplant coronary artery disease is a predictor for myocardial infarction and cardiac death after liver transplantation. Eur J Intern Med 2018; 51: 41-45.
19. Buggisch P, Vermehren J, Mauss S, Günther R, Schott E, Pathil A, Boeker K, Zimmermann T, Teuber G, Vornkahl HP, Simon KG, Niederau C, Wedemeyer H, Zeuzem S. Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C. J Hepatol 2017; doi 10.1016/j.hep.2017.11.009.
20. Bernuth S, Grimm D, Vollmar J, Darstein F, Mittler J, Heise M, Hoppe-Lotichius M, Galle PR, Lang H, Zimmermann T. Efficacy and safety of direct-acting antiviral therapy in previous hard-to-treat patients with recurrent hepatitis C virus infection after liver transplantation: a real-world cohort. Drug Des Devel Ther 2017; 11: 2131-2138.
21. Welzel TM, Hinrichsen H, Sarrazin C, Buggisch P, Baumgarten A, Christensen S, Berg T, Mauss S, Teuber G, Stein K, Deterding K, van Bömmel F, Heyne R, John C, Zimmermann T, Lutz T, Schott E, Hettinger J, Kleine H, König B, Hüppe D, Wedemeyer H. Real-world experience with the all-oral interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry. Journal of Viral Hepat 2017; 24(10): 840-849.
22. Nagel M, Schwarting A, Straub BK, Galle PR, Zimmermann T. Hepatische Manifestation eines Makrophagen-Aktivierungs-Syndroms (MAS). Z Gastroenterol 2017; 55(5): 473-478.
23. Zimmermann T, Beckebaum S, Berg C, Berg T, Braun F, Eurich D, Herzer K, Neumann U, Rupp C, Sterneck M, Strassburg C, Welker MW, Zachoval R, Gotthardt DN, Weigand K, Schmidt H, Wedermeyer H, Galle PR, Zeuzem S, Sarrazin C. Expert recommendations: Hepatitis C and transplantation. Z Gastroenterol 2016; 54(7): 665-684.
24. Zimmermann T, Hueppe D, Mauss S, Buggisch P, Pfeiffer-Vornkahl H, Grimm D, Galle PR, Alshuth U. Effects of smoking on pegylated interferon alpha 2a and first generation protease inhibitor-based antiviral therapy in naïve patients infected with hepatitis C virus genotype 1. J Gastrointestin Liver Dis 2016; 25(1): 15-24.
25. Grimm D, Lieb J, Weyer V, Vollmar J, Darstein F, Lautem A, Hoppe-Lotichius M, Koch S, Schad A, Schattenberg JM, Wörns MA, Weinmann A, Galle PR, Zimmermann T. Organic cation transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatment. BMC Cancer 2016; 16: 94.
26. Herzer K, Strassburg CP, Braun F, Engelmann C, Guba M, Lehner F, Nadalin S, Pascher A, Scherer MN, Schnitzbauer AA, Zimmermann T, Nashan B, Sterneck M. Selection and use of immunosuppressive therapies after liver transplantation: current German practice. Clin Transplant 2016; 30(5): 487-501.
27. Zimmermann A, Zobeley C, Weber MM, Lang H, Galle PR, Zimmermann T. Changes in lipid and carbohydrate metabolism under mTOR- and calcineurin-based immunosuppressive regimen in adult patients after liver transplantation. Eur J Intern Med 2016; 29: 104-109.
28. Vollmar J, Bellmann MC, Darstein F, Hoppe-Lotichius M, Mittler J, Heise M, Rüttger B, Weyer V, Zimmermann A, Lang H, Galle PR, Zimmermann T. Efficacy and safety of a conversion from the original tacrolimus and mycophenolate mofetil to the generics Tacpan and Mowel after liver transplantation. Drug Des Devel Ther 2015; 9: 6139-6149.
29. Bernuth S, Yagmur E, Schuppan D, Sprinzl MF, Zimmermann A, Schad A, Kittner JM, Weyer V, Knapstein J, Schattenberg JM, Wörns MA, Galle PR, Zimmermann T. Early changes in dynamic biomarkers of liver fibrosis in hepatitis C virusinfected patients treated with sofosbuvir. Dig Liver Dis 2016; 48(3): 291-297.
30. Steinebrunner N, Sprinzl MF, Zimmermann T, Wörns MA, Zimmerer T, Galle PR, Stremmel W, Eisenbach C, Stein K, Antoni C, Schattenberg JM, Pathil A. Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multicenter “real-life” cohort. BMC Gastroenterol. 2015; 15: 97.
31. Zimmermann A, Grigorescu-Sido P, Rossmann H, Lackner KJ, Drugan C, Al Khzouz C, Bucerzan S, Nascu I, Radu PA, Zimmermann T, Weber MM. A prospective study of insulin resistance in Gaucher Disease Type 1 patients with normal weight, under enzyme replacement therapy. Acta Endocrinologica 2015; 11(2): 180-188.
32. Darstein F, König C, Hoppe-Lotichius M, Grimm D, Knapstein J, Zimmermann A, Mittler J, Schattenberg JM, Sprinzl MF, Wörns MA, Lang H, Galle PR, Zimmermann T. New onset of diabetes after transplantation is associated with improved patient survival after liver transplantation due to confounding factor. Eur J Intern Med 2015; 26(6): 439-444.
33. Weinmann A, Alt Y, Koch S, Nelles C, Düber C, Lang H, Otto G, Zimmermann T, Marquardt JU, Galle PR, Wörns MA, Schattenberg JM. Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma. BMC Cancer 2015; 15: 210.
34. Tug S, Helmig S, Deichmann ER, Schmeier-Jürchott A, Wagner E, Zimmermann T, Radsak M, Giacca M, Simon P. Exercise-induced increases in cell free DNA in human plasma originate predominantly from cells of the haematopoietic lineage. Exerc Immunol Rev 2015; 21: 164-73.
35. Gehrke N, Garcia-Bardon D, Mann A, Schad A, Alt Y, Wörns MA, Sprinzl MF, Zimmermann T, Menke J, Engstler AJ, Bergheim I, He YW, Galle PR, Schuchmann M, Schattenberg JM. Acute organ failure following the loss of anti-apoptotic cellular FLICE-inhibitory protein involves activation of innate immune receptors. Cell Death Differ. 2015; 22(5): 826-37.
36. Niederau C, Mauss S, Schober A, Stoehr A, Zimmermann T, Waizmann M, Moog G, Pape S, Weber B, Isernhagen K, Sandow P, Bokemeyer B, Alshuth U, Steffens H, Hüppe D. Predictive factors for sustained virological response after treatment with pegylated interferon a-2a and ribavirin in patients infected with HCV genotypes 2 and 3. PLoS One. 2014; 9(9):e107592.
37. Sivanathan V, Kittner JM, Sprinzl MF, Weinmann A, Koch S, Wiltink J, Nguyen-Tat M, Marquardt JU, Wörns MA, Zimmermann T, Lang H, Galle PR, Schattenberg JM. [Etiology and complications of liver cirrhosis: data from a German centre]. Dtsch Med Wochenschr. 2014; 139(36): 1758-62.
38. Knapstein J, Wörns MA, Galle PR, Zimmermann T. Combination therapy with silibinin, pegylated interferon and ribavirin in a patient with hepatitis C virus genotype 3 reinfection after liver transplantation: a case report. J Med Case Rep. 2014; 8(1): 257.
39. Farnik H, Zimmermann T, Herrmann E, Bechstein WO, Kronenberger B, Galle PR, Labocha S, Ferreiros N, Geisslinger G, Zeuzem S, Sarrazin C, Welker MW. Telaprevir drug monitoring during antiviral therapy of hepatitis C graft infection after liver transplantation. Liver Int. 2014; doi: 10.1111
40. Darstein F, König C, Hoppe-Lotichius M, Grimm D, Knapstein J, Mittler J, Zimmermann A, Otto G, Lang H, Galle PR, Zimmermann T. Preoperative left ventricular hypertrophy is associated with reduced patient survival after liver transplantation. Clin Transplant. 2014; 28(2): 236-242.
41. Darstein F, König C, Hoppe-Lotichius M, Grimm D, Knapstein J, Mittler J, Zimmermann A, Otto G, Lang H, Galle PR, Zimmermann T. Impact of pancreatic comorbidities in patients with end-stage liver disease on the outcome after liver transplantation. Eur J Intern Med. 2014; 25(3): 282-285.
42. Darstein F, Kirschey S, Heckl S, Rahman F, Schwarting A, Schuchmann M, Galle PR, Zimmermann T. Successful treatment of Erdheim-Chester disease with combination of interleukin-1-targeting drugs and high-dose glucocorticoids. Intern Med J. 2014; 44(1): 90-92.
43. Foltys D, Zimmermann T, Kaths M, Strempel M, Heise M, Hoppe-Lotichius M, Weiler N, Scheuermann M, Ruckes C, Hansen T, Pitton M, Otto G. Hepatocellular carcinoma in Child’s A cirrhosis: a retrospective analysis of matched pairs following liver transplantation vs. liver resection according to the intention-to-treat principle. Clin Transplant. 2014; 28(1): 37-46.
44. Knapstein J, Galle PR, Zimmermann T. Antiviral triple therapy with boceprevir in a chronic hepatitis C hemodialysis patient awaiting kidney re-transplantation. Dig Liver Dis. 2014; 46(1): 88-89.
45. Kittner JM, Weiss NM, Wiltink J, Schattenberg JM, Grambihler A, Thieringer F, Weinmann A, Zimmermann T, Koch S, Schuchmann M, Galle PR. Defer or treat? Reasons for treatment decisions in patients with chronic hepatitis C genotype 1 in the early era of directly acting antiviral agents. Dig Liver Dis. 2014; 46(1): 67-71.
46. Weiler N, Thrun I, Eberlin M, Foltys D, Heise M, Hoppe-Lotichius M, Zimmermann T, Kraemer I, Otto G. Tacrolimus effects and side effects after liver transplantation: is there a difference between immediate and extended release? Transplant Proc. 2013; 45(6): 2321-2325.
47. Kohl T, Gehrke N, Schad A, Nagel M, Wörns MA; Sprinzl MF, Zimmermann T, He YW, Galle PR, Schuchmann M, Schattenberg JM. Diabetic liver injury from streptozotocin is regulated through the caspase-8 homolog cFLIP involving activation of JNK2 and intrahepatic immunocompetent cells. Cell Death Dis. 2013; 4: e712.
48. Lautem A, Heise M, Gräsel A, Hoppe-Lotichius M, Weiler N, Foltys D, Knapstein J, Schattenberg JM, Schad A, Zimmermann A, Otto G, Lang H, Galle PR, Schuchmann M, Zimmermann T. Downregulation of organic cation transporter 1 (SLC22A1) is associated with tumor progression and reduced patient survival in human hepatocellular carcinoma. Int J Oncol. 2013; 42(4): 1297-1304.
49. Schuchmann M, Kittner JM, Schlaak JF, Klass DM, Eisenbach C, Berg T, Trautwein C, Günther R, Zeuzem S, Gösseringer R, Ehrlich A, Neumann K, Wachtlin D, Sprinzl MF, Zimmermann T, Böcher WO, Galle PR. No beneficial effect of all-trans retinoic acid in previous non-responder patients with chronic hepatitis C: the ATRACTION study, a phase II randomised trial. Dig Liver Dis. 2013; 45(4): 323-329.
50. Sprinzl MF, Weinmann A, Lohse N, Tönissen H, Koch S, Schattenberg J, Hoppe-Lotichius M, Zimmermann T, Galle PR, Hansen T, Otto G, Schuchmann M. Metabolic syndrome and its association with fatty liver disease after orthotopic liver transplantation. Transpl Int. 2013; 26(1): 67-74.
51. Zimmermann A, Grigorescu-Sido P, Rossmann H, Lackner KJ, Drugan C, Al Khzouz C, Bucerzan S, Naşcu I, Zimmermann T, Leucuţa D, Weber MM. Dynamic changes of lipid profile in Romanian patients with Gaucher disease type 1 under enzyme replacement therapy: a prospective study. J Inherit Metab Dis. 2013; 36(3): 555-563.
52. Schattenberg JM, Nagel M, Kim YO, Kohl T, Wörns MA, Zimmermann T, Schad A, Longerich T, Schuppan D, He YW, Galle PR, Schuchmann M. Increased hepatic fibrosis and JNK2-dependent liver injury in mice exhibiting hepatocyte-specific deletion of cFLIP. Am J Physiol Gastrointest Liver Physiol. 2012; 303(4): G498-506.
53. Teufel A, Becker D, Weber SN, Dooley S, Breitkopf-Heinlein K, Maass T, Hochrath K, Krupp M, Marquardt JU, Kolb M, Korn B, Niehrs C, Zimmermann T, Godoy P, Galle PR, Lammert F. Identification of RARRES1 as a core regulator in liver fibrosis. J Mol Med 2012; 90(12): 1439-1447.
54. Kashyap A, Zimmermann T, Ergül N, Bosserhoff A, Hartmann U, Alla V, Bataille F, Galle PR, Strand S, Strand D. The human Lgl polarity gene, Hugl-2, induces MET and suppresses Snail tumorigenesis. Oncogene 2013; 32(11): 1396-1407.
55. Heise M, Lautem A, Knapstein J, Schattenberg JM, Hoppe-Lotichius M, Foltys D, Weiler N, Zimmermann A, Schad A, Gründemann D, Otto G, Galle PR, Schuchmann M, Zimmermann T. Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance. BMC Cancer 2012; 22(1): 382-385.
56. Schattenberg JM, Wörns MA, Zimmermann T, He YW, Galle PR, Schuchmann M. The role of death effector domain-containing proteins in acute oxidative cell injury in hepatocytes. Free Radical Biology and Medicine 2012; 52(9): 1911-1917.
57. Foltys DB, Kaths JM, Zimmermann T, Heise M, Hoppe-Lotichius M, Otto G. Ten years of simultaneous pancreas-kidney transplantation: a retrospective single-center analysis of prospectively obtained data. Transplantation Proceedings 2011; 43(9): 3267-3269.
58. Foltys D, Heise M, Hadian A, Lautem A, Wisser G, Zimmermann T, Weiler N, Hoppe-Lotichius M, Peixoto N, Symkange-Zeeb F, Otto G. Liver transplantation for hepatocellular carcinoma – is there a risk of recurrence caused by intraoperative blood salvage autotransfusion? European Surgical Research 2011; 47(3): 182-187.
59. Wehler TC, Graf C, Altherr K, Zimmermann T, Brenner W, Thüroff JW, Biesterfeld S, Gockel I, Theobald M, Galle PR, Schimanski CC. SDF1β expression in renal cell carcinoma correlates with grading and infiltration by CD8+ T-cells. Anticancer Research 2011; 31(9): 2797-2803.
60. Zimmermann T, Hoppe-Lotichius M, Körner A, Lautem A, Heise M, Foltys D, Weiler N, Biesterfeld S, Schmidtmann I, Galle PR, Otto G, Schuchmann M. The recipient CYP2D6 allele 4-associated poor metabolizer status correlates with an early fibrosis development after liver transplantation. Transplant international 2011; 24(11): 1059-1067.
61. Schattenberg J, Zimmermann T, Wörns M, Sprinzl MF, Kreft A, Kohl T, Nagel M, Siebler J, Bergkamen HS, He YW, Galle PR, Schuchmann M. Ablation of c-FLIP in hepatocytes enhances death-receptor mediated apoptosis and toxic liver injury in vivo. Journal of Hepatology 2011; 55(6): 1272-1280.
62. Zimmermann A*, Zimmermann T*, Schattenberg J, Pöttgen S, Lotz J, Rossmann H, Röddiger R, Biesterfeld S, Geiss CH, Schuchmann M, Galle PR, Weber MM. Alterations in lipid, carbohydrate and iron metabolism in patients with NASH and metabolic syndrome. European Journal of Internal Medicine 2011; 22(3): 305-310. * Co-Erstautor
63. Schimanski CC, Moehler M, Zimmermann T, Wörns MA, Steinbach A, Baum M, Galle PR. Cetuximab-induced skin exanthema: Improvement by a reactive skin therapy. Molecular Medicine Reports 2010; 3(5): 789-794.
64. Schimanski CC, Möhler M, Gockel I, Zimmermann T, Lang H, Galle PR, Berger MR. Expression of chemokine receptor CCR5 correlates with the presence of hepatic molecular metastases in K-ras positive human colorectal cancer. Journal of Cancer Research and Clinical Oncology 2011; 137(7): 1139-1345.
65. Hartmann I, Schuchmann M, Zimmermann T. Posttransplant lymphoproliferative disease in liver transplant patients. Current Infectious Disease Reports 2011; 13: 53-59. 
66. Weiler N, Thrun I, Hoppe-Lotichius M, Zimmermann T, Kraemer I, Otto G. Early steroid-free immunosuppression with FK506 after liver transplantation: long-term results of a prospectively randomized double-blinded trial. Transplantation 2010; 90(12): 1562-1566.
67. Zimmermann T, Hoppe-Lotichus M, Tripkovic V, Barreiros AP, Wehler TC, Zimmermann A, Schattenberg JM, Heise M, Biesterfeld S, Galle PR, Otto G, Schuchmann M. Liver transplanted patients with preoperative autoimmune hepatitis and immunological disorders are at increased risk for Post-Transplant Lymphoproliferative Disease (PTLD). European Journal of Internal Medicine 2010; 21(3): 208-215.
68. Schimanski CC, Moehler M, Zimmermann T, Gockel I, Lang H, Arbogast R, Jäger D, Galle PR, Berger MR. [Detection of hepatic micrometastases in the context of adjuvant chemotherapy and surgery for hepatic metastases.] Deutsche Medizinische Wochenschrift 2010; 135(21): 1078-1082.
69. Zimmermann A, Grigorescu Sido P, AlKhzouz C, Patberg K, Bucerzan S, Schulze E, Zimmermann T, Roßmann H, Geiss Ch, Lackner KJ, Weber MM. Alterations in lipid and carbohydrate metabolism in patients with classic CAH due to 21-hydroxylase deficiency. Hormone Research in Paediatrics 2010; 74(1):41-9. 
70. Zimmermann T, Moehler M, Gockel I, Sgourakis GG, Biesterfeld S, Müller M, Berger MR, Lang H, Galle PR, Schimanski CC. Low expression of chemokine receptor CCR5 in human colorectal cancer correlates with lymphatic dissemination and reduced CD8+ T-cell infiltration. International Journal of Colorectal Disease 2010; 25(4): 417-424.  
71. Schimanski CC, Zimmermann T, Schmidtmann I, Gockel I, Lang H, Galle PR, Moehler M, Berger MR. K-ras mutation status correlates with the expression of VEGFR1, VEGFR2, and PDGFRalpha in colorectal cancer. International Journal of Colorectal Disease 2010; 25(2):181-186.
72. Zimmermann T, Otto C, Biesterfeld S, Zimmermann A, Barreiros AP, Sprinzl MF, Otto G, Galle PR, Schuchmann M. Risk factors in patients with rapid recurrent HCV related cirrhosis within one year after liver transplantation. Transplantation Proceedings 2009; 41(6): 2549-2556.
73. Zimmermann T, Kashyap A, Hartmann U, Otto G, Galle PR, Strand S, Strand D. Cloning and characterization of the promoter of Hugl-2, the human homologue of Drosophila lethal giant larvae (lgl) polarity gene. Biochemical and Biophysical Research Communications 2008; 366(4): 1067-1073.
74. Zimmermann A, Schenk JP, Grigorescu Sido P, Pfäffle R, Lazea C, Zimmermann T, Heinrich U, Weber MM, Bettendorf M. MRI findings and genotype analysis in patients with childhood onset growth hormone deficiency. Correlation with severity of hypopituitarism. Journal of Pediatric Endocrinology and Metabolism 2007; 20(5):587-96. 
75. Zimmermann T, Böcher WO, Biesterfeld S, Zimmermann A, Kanzler S, Greif-Higer G, Barreiros AP, Sprinzl MF, Wörns MA, Lohse AW, Mönch C, Otto G, Galle PR, Schuchmann M. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation. Transplant International 2007; 20(7): 583-590.      
76. Lazar A*, Zimmermann T*, Koch W, Gründemann D, Schömig A, Kastrati A, Schömig E. Lower prevalence of the OCT2 Ser270 allele in patients with essential hypertension. Clinical and Experimental Hypertension 2006; 28: 645-653.   * Co-Erstautor          
77. Zimmermann T, Maccagno G, Galle PR, Otto G, Hitzler WE, Schuchmann M. Alloimmune hemolytic anemia after liver transplantation from an ABO-identical and Rh-nonidentical donor in a patient with postpartum Budd-Chiari syndrome. Transplant international 2006; 19(6): 514-515.
78. Lazar A, Gründemann D, Berkels R, Taubert D, Zimmermann T, Schömig E. Genetic variability of the extraneuronal monoamine transporter EMT (SLC22A3). Journal of Human Genetics 2003; 48: 226-230.
79. Gründemann D, Koschker AC, Haag C, Honold C, Zimmermann T, Schömig E. Activation of the extraneuronal monoamine transporter (EMT) from rat expressed in 293 cells. British Journal of Pharmacology 2002; 137(6): 910-918.